Lantheus Holdings, Inc. (NASDAQ:LNTH) Stock Position Lifted by Sirios Capital Management L P

Sirios Capital Management L P lifted its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 22.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 23,183 shares of the medical equipment provider's stock after purchasing an additional 4,310 shares during the quarter. Sirios Capital Management L P's holdings in Lantheus were worth $2,074,000 at the end of the most recent reporting period.

Other institutional investors have also bought and sold shares of the company. T. Rowe Price Investment Management Inc. raised its stake in shares of Lantheus by 40.5% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,509,332 shares of the medical equipment provider's stock worth $135,025,000 after buying an additional 435,445 shares in the last quarter. Reinhart Partners LLC. grew its holdings in Lantheus by 9.9% during the fourth quarter. Reinhart Partners LLC. now owns 1,366,873 shares of the medical equipment provider's stock worth $122,280,000 after acquiring an additional 123,282 shares during the period. Dimensional Fund Advisors LP raised its position in Lantheus by 2.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,347,082 shares of the medical equipment provider's stock worth $120,510,000 after acquiring an additional 30,891 shares in the last quarter. Swedbank AB lifted its holdings in Lantheus by 53.3% in the 4th quarter. Swedbank AB now owns 1,107,243 shares of the medical equipment provider's stock valued at $99,054,000 after acquiring an additional 385,000 shares during the last quarter. Finally, Portolan Capital Management LLC boosted its position in shares of Lantheus by 21.1% during the 4th quarter. Portolan Capital Management LLC now owns 812,630 shares of the medical equipment provider's stock valued at $72,698,000 after purchasing an additional 141,749 shares in the last quarter. Institutional investors and hedge funds own 99.06% of the company's stock.

Lantheus Stock Down 1.0 %

LNTH opened at $99.57 on Wednesday. The firm has a market capitalization of $6.82 billion, a P/E ratio of 16.57 and a beta of 0.20. The stock has a fifty day moving average of $96.11 and a 200-day moving average of $95.36. Lantheus Holdings, Inc. has a 12-month low of $62.59 and a 12-month high of $126.89.

Lantheus (NASDAQ:LNTH - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.57 by ($0.23). The business had revenue of $391.11 million during the quarter, compared to analysts' expectations of $376.61 million. Lantheus had a return on equity of 44.29% and a net margin of 28.57%. On average, analysts expect that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CFO Robert J. Jr. Marshall sold 10,000 shares of Lantheus stock in a transaction on Monday, March 17th. The stock was sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the completion of the sale, the chief financial officer now owns 113,860 shares of the company's stock, valued at approximately $11,445,207.20. This trade represents a 8.07 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Mary Anne Heino sold 53,107 shares of the company's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $94.35, for a total value of $5,010,645.45. Following the completion of the transaction, the director now directly owns 440,399 shares in the company, valued at approximately $41,551,645.65. The trade was a 10.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 63,109 shares of company stock worth $6,016,046 in the last quarter. 2.00% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

LNTH has been the subject of a number of research reports. B. Riley reduced their target price on shares of Lantheus from $127.00 to $122.00 and set a "buy" rating for the company in a report on Friday, March 21st. JMP Securities reissued a "market outperform" rating and set a $112.00 price objective on shares of Lantheus in a research note on Tuesday, January 14th. Finally, Truist Financial boosted their target price on Lantheus from $120.00 to $127.00 and gave the stock a "buy" rating in a research report on Thursday, February 27th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $129.43.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.